and renal damage, whereas a larger proportion of patients showing carotid plaque regression was observed under zofenopril (31.6% vs. 16.1%; p = 0.047). Interestingly, in the subgroup of patients taking the low dose of zofenopril (30 mg) plus HCTZ 12.5 mg the rate of those exhibiting a carotid plaque at study end was significantly lower than that in the subgroup of patients taking the low dose of irbesartan (150 mg) plus HCTZ 12.5 mg (4.7% vs 10.0%; p = 0.043)''.
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